S&P 500   4,582.13 (-1.57%)
DOW   34,568.55 (-1.61%)
QQQ   393.03 (-1.67%)
AAPL   163.47 (+2.02%)
MSFT   330.31 (-1.88%)
FB   326.20 (-3.50%)
GOOGL   2,849.93 (-2.08%)
AMZN   3,505.39 (-1.58%)
TSLA   1,130.35 (-0.58%)
NVDA   321.34 (-3.72%)
BABA   127.28 (-3.29%)
NIO   38.82 (-4.05%)
CGC   10.40 (-5.97%)
AMD   156.71 (-3.21%)
GE   94.66 (-3.80%)
MU   84.46 (-1.95%)
T   22.62 (-5.32%)
F   19.17 (-2.54%)
DIS   144.12 (-2.50%)
ACB   6.19 (-3.88%)
AMC   33.88 (-8.03%)
PFE   54.13 (+3.30%)
BA   194.69 (-1.92%)
S&P 500   4,582.13 (-1.57%)
DOW   34,568.55 (-1.61%)
QQQ   393.03 (-1.67%)
AAPL   163.47 (+2.02%)
MSFT   330.31 (-1.88%)
FB   326.20 (-3.50%)
GOOGL   2,849.93 (-2.08%)
AMZN   3,505.39 (-1.58%)
TSLA   1,130.35 (-0.58%)
NVDA   321.34 (-3.72%)
BABA   127.28 (-3.29%)
NIO   38.82 (-4.05%)
CGC   10.40 (-5.97%)
AMD   156.71 (-3.21%)
GE   94.66 (-3.80%)
MU   84.46 (-1.95%)
T   22.62 (-5.32%)
F   19.17 (-2.54%)
DIS   144.12 (-2.50%)
ACB   6.19 (-3.88%)
AMC   33.88 (-8.03%)
PFE   54.13 (+3.30%)
BA   194.69 (-1.92%)
S&P 500   4,582.13 (-1.57%)
DOW   34,568.55 (-1.61%)
QQQ   393.03 (-1.67%)
AAPL   163.47 (+2.02%)
MSFT   330.31 (-1.88%)
FB   326.20 (-3.50%)
GOOGL   2,849.93 (-2.08%)
AMZN   3,505.39 (-1.58%)
TSLA   1,130.35 (-0.58%)
NVDA   321.34 (-3.72%)
BABA   127.28 (-3.29%)
NIO   38.82 (-4.05%)
CGC   10.40 (-5.97%)
AMD   156.71 (-3.21%)
GE   94.66 (-3.80%)
MU   84.46 (-1.95%)
T   22.62 (-5.32%)
F   19.17 (-2.54%)
DIS   144.12 (-2.50%)
ACB   6.19 (-3.88%)
AMC   33.88 (-8.03%)
PFE   54.13 (+3.30%)
BA   194.69 (-1.92%)
S&P 500   4,582.13 (-1.57%)
DOW   34,568.55 (-1.61%)
QQQ   393.03 (-1.67%)
AAPL   163.47 (+2.02%)
MSFT   330.31 (-1.88%)
FB   326.20 (-3.50%)
GOOGL   2,849.93 (-2.08%)
AMZN   3,505.39 (-1.58%)
TSLA   1,130.35 (-0.58%)
NVDA   321.34 (-3.72%)
BABA   127.28 (-3.29%)
NIO   38.82 (-4.05%)
CGC   10.40 (-5.97%)
AMD   156.71 (-3.21%)
GE   94.66 (-3.80%)
MU   84.46 (-1.95%)
T   22.62 (-5.32%)
F   19.17 (-2.54%)
DIS   144.12 (-2.50%)
ACB   6.19 (-3.88%)
AMC   33.88 (-8.03%)
PFE   54.13 (+3.30%)
BA   194.69 (-1.92%)
NASDAQ:BTTX

Better Therapeutics Stock Forecast, Price & News

$6.19
-0.87 (-12.32%)
(As of 11/30/2021 01:17 PM ET)
Add
Compare
Today's Range
$6.10
$7.01
50-Day Range
N/A
52-Week Range
$6.36
$29.40
Volume
7,207 shs
Average Volume
6.69 million shs
Market Capitalization
$46.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive BTTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Better Therapeutics

Better Therapeutics Inc. is a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases. Better Therapeutics Inc., formerly known as Mountain Crest Acquisition Corp II, is based in SAN FRANCISCO.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Health services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTTX
Fax
N/A
Employees
1
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.02 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$46.80 million
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

625th out of 1,390 stocks

Health Services Industry

6th out of 14 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Better Therapeutics (NASDAQ:BTTX) Frequently Asked Questions

Is Better Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Better Therapeutics stock.
View analyst ratings for Better Therapeutics
or view top-rated stocks.

What price target have analysts set for BTTX?

2 equities research analysts have issued 1-year target prices for Better Therapeutics' stock. Their forecasts range from $17.00 to $17.00. On average, they anticipate Better Therapeutics' share price to reach $17.00 in the next twelve months. This suggests a possible upside of 174.6% from the stock's current price.
View analysts' price targets for Better Therapeutics
or view top-rated stocks among Wall Street analysts.

What is Better Therapeutics' stock symbol?

Better Therapeutics trades on the NASDAQ under the ticker symbol "BTTX."

How do I buy shares of Better Therapeutics?

Shares of BTTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Better Therapeutics' stock price today?

One share of BTTX stock can currently be purchased for approximately $6.19.

How much money does Better Therapeutics make?

Better Therapeutics has a market capitalization of $46.80 million.

How many employees does Better Therapeutics have?

Better Therapeutics employs 1 workers across the globe.

What is Better Therapeutics' official website?

The official website for Better Therapeutics is mcacquisition.com.

Where are Better Therapeutics' headquarters?

Better Therapeutics is headquartered at 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036.

How can I contact Better Therapeutics?

Better Therapeutics' mailing address is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 646-493-6558 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.